Table 1 Patient and treatment characteristics.
Factor | Group | Values |
|---|---|---|
(n = 129) | ||
Age | 65.00 [33.00, 88.00] | |
Gender | F | 34 (26.4) |
M | 95 (73.6) | |
Chemotherapy (%) | No | 126 (97.7) |
Yes | 3 ( 2.3) | |
Previous surgery (%) | No | 79 (61.2) |
Yes | 50 (38.8) | |
Primary site (%) | Hypopharynx | 12 ( 9.3) |
Oral | 32 (24.8) | |
Larynx | 5 ( 3.9) | |
Nasopharynx | 56 (43.4) | |
Oropharynx | 24 (18.6) | |
Histology | Squamous cell carcinoma | 125 (97) |
Adenoid cystic carcinoma | 1 (0.8) | |
Adenocarcinoma | 2 (1.5) | |
Verrucous carcinoma | 1 (0.8) | |
rT category | 1 | 39 (30.2) |
2 | 29 (22.5) | |
3 | 23 (17.8) | |
4 | 36 (27.9) | |
Not available | 2 (1.5) | |
Lymph node involvement (%) | No | 108 (78.8) |
Yes | 29 (21.2) | |
GTV (cm3) | 23.70 [0.91, 339.60] | |
Interval (months) | 19.00 [3, 284.40] | |
Prescribed dose (Gy) | 30.00 [15.00, 69.00] | |
fraction | 5.00 [1.00, 30.00] | |
EQD2 (α/β = 10) (Gy) | 40.00 [18.95, 74.75] | |
Previous prescribed dose (Gy) | 60.00 [32.00, 74.80] | |
Previous fraction | 30.00 [5.00, 62.00] | |
Follow-up times (months) | 10.6 [0.10, 122] |
